N@N

Market Maker Surveillance Report. ACUR, MCP, CBMX, UNXL, INFI, CLDX, Winning Stocks With Lowest Price Friction For Monday, Dec

December 10, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4068 companies with "abnormal" market making, 3029 companies with positive Friction Factors and 2618 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Acura Pharmaceuticals Inc (NASDAQ:ACUR), Molycorp Inc (NYSE:MCP), CombiMatrix Corp (NASDAQ:CBMX), Uni-Pixel Inc (NASDAQ:UNXL), Infinity Pharmaceuticals Inc (NASDAQ:INFI), Celldex Therapeutics Inc (NASDAQ:CLDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  ACUR    $1.020    71.33%    1,656,606    56.66%    1,255,374    42.94%    401,232      3,934   
  MCP     $1.780    19.91%    9,641,640    43.28%    8,326,609    37.38%    1,315,031    7,388   
  CBMX    $2.050    23.84%    1,488,273    50.39%    1,423,624    48.20%    64,649       315     
  UNXL    $5.150    52.82%    1,695,378    51.65%    1,549,319    47.20%    146,059      284     
  INFI    $4.780    21.20%    1,935,636    49.77%    1,924,562    49.48%    11,074       23      
  CLDX    $1.410    25.54%    5,033,508    51.20%    4,778,815    48.61%    254,693      1,806   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ACUR with a dollar gain Monday of $1.02000 and a Friction Factor of 3,934 shares. That means that it only took 3,934 more shares of buying than selling to move ACUR higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Acura Pharmaceuticals Inc (NASDAQ:ACUR) - Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion Technology, Impede Technology, and other technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, decongestants, and various other opioid analgesics. The companys lead product candidate, Acurox Tablet, is an orally administered immediate release tablet containing oxycodone HCl as its active analgesic ingredient. Its opioid analgesic product candidates are used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. The company is also investigating and developing mechanisms to incorporate abuse deterrent characteristics into abused and misused pharmaceutical products through laboratory testing of a product candidate developed with its Impede Technology, which is intended to inhibit the conversion of pseudoephedrine HCl into methamphetamine. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize various opioid analgesic products utilizing the companys proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois..

Molycorp Inc (NYSE:MCP) - Molycorp, Inc., a development stage company, focuses on the production and sale of rare earth oxides from stockpiled feedstocks in the western hemisphere. The company operates the Mountain Pass mine, a non-Chinese rare earth deposit located in San Bernardino County, California. Its rare earth products are used as inputs in various existing and emerging applications comprising clean energy technologies; multiple high-tech uses; defense applications; and water treatment technology. The company was founded in 2008 and is headquartered in Greenwood Village, Colorado..

CombiMatrix Corp (NASDAQ:CBMX) - CombiMatrix Corporation develops proprietary technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, and defense and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins. The companys products and services include CustomArray platform, an oligonucleotide array for genetic studies; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. It also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, it operates as a diagnostics reference laboratory, which provides genetic diagnostics services through the use of arrays that utilize bacterial artificial chromosomes that enable genetic analysis to physicians, hospitals, and clinics. Further, the company develops a series of compounds to address various oncology-related diseases. Additionally, it involves in the development, manufacture, and sale of biosensor systems and technology for national defense and homeland security. The company sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia. CombiMatrix Corporation was founded in 1995 and is based in Mukilteo, Washington..

Uni-Pixel Inc (NASDAQ:UNXL) - Uni-Pixel, Inc., a development stage company, focuses on the research, development, and commercialization of flat panel displays using its Time Multiplexed Optical Shutter (TMOS) technology. The TMOS technology is used in various applications, such as mobile phones, digital cameras, notebook computers, televisions, and other consumer electronic devices. The company was founded in 1998 and is headquartered in The Woodlands, Texas..

Infinity Pharmaceuticals Inc (NASDAQ:INFI) - Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers. The company is headquartered in Cambridge, Massachusetts..

Celldex Therapeutics Inc (NASDAQ:CLDX) - Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms. Its precision targeted immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates, and immunomodulators to create disease-specific drug candidates. The company offers Rotarix for the treatment of rotavirus infection. Its clinical development programs include CDX-110, which is in Phase IIb clinical trail for the treatment of glioblastoma multiforme; CDX-011 that is in Phase II clinical trial to treat metastatic melanoma and breast cancer; and CDX-1307, a Phase I clinical trial product for treating colorectal, bladder, pancreas, ovarian, and breast tumors, as well as CDX-1401 and CDX-1135, which are in Phase I/II clinical trials for the treatment of multiple solid tumors and renal diseases respectively. The companys preclinical product candidates comprise CDX-301 for treating cancer, and autoimmune diseases and transplants; CDX-1127 for immuno-modulation and multiple tumors; CDX-014 to treat renal and ovarian cancer; and CDX-1189 for renal diseases. It has collaborative partnership agreements with GlaxoSmithKline plc; Pfizer Inc.; Vaccine Technologies, Inc.; and TopoTarget A/S, as well as research collaboration and licensing agreements with Medarex, Inc.; Alteris Therapeutics, Inc.; 3M Company; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company was founded in 1983 and is headquartered in Needham, Massachusetts..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net